641 related articles for article (PubMed ID: 32152485)
1. Lineage plasticity in cancer: a shared pathway of therapeutic resistance.
Quintanal-Villalonga Á; Chan JM; Yu HA; Pe'er D; Sawyers CL; Sen T; Rudin CM
Nat Rev Clin Oncol; 2020 Jun; 17(6):360-371. PubMed ID: 32152485
[TBL] [Abstract][Full Text] [Related]
2. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.
Ku SY; Rosario S; Wang Y; Mu P; Seshadri M; Goodrich ZW; Goodrich MM; Labbé DP; Gomez EC; Wang J; Long HW; Xu B; Brown M; Loda M; Sawyers CL; Ellis L; Goodrich DW
Science; 2017 Jan; 355(6320):78-83. PubMed ID: 28059767
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
[TBL] [Abstract][Full Text] [Related]
4. Biology and evolution of poorly differentiated neuroendocrine tumors.
Rickman DS; Beltran H; Demichelis F; Rubin MA
Nat Med; 2017 Jun; 23(6):1-10. PubMed ID: 28586335
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas.
Jin Y; Shi X; Zhao J; He Q; Chen M; Yan J; Ou Q; Wu X; Shao YW; Yu X
Lung Cancer; 2018 Oct; 124():110-116. PubMed ID: 30268447
[TBL] [Abstract][Full Text] [Related]
6. Long non-coding RNAs in lung cancer: implications for lineage plasticity-mediated TKI resistance.
Liu T; Han C; Fang P; Zhu H; Wang S; Ma Z; Zhang Q; Xia W; Wang J; Xu L; Yin R
Cell Mol Life Sci; 2021 Mar; 78(5):1983-2000. PubMed ID: 33170304
[TBL] [Abstract][Full Text] [Related]
7.
Blee AM; He Y; Yang Y; Ye Z; Yan Y; Pan Y; Ma T; Dugdale J; Kuehn E; Kohli M; Jimenez R; Chen Y; Xu W; Wang L; Huang H
Clin Cancer Res; 2018 Sep; 24(18):4551-4565. PubMed ID: 29844131
[No Abstract] [Full Text] [Related]
8. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.
Mu P; Zhang Z; Benelli M; Karthaus WR; Hoover E; Chen CC; Wongvipat J; Ku SY; Gao D; Cao Z; Shah N; Adams EJ; Abida W; Watson PA; Prandi D; Huang CH; de Stanchina E; Lowe SW; Ellis L; Beltran H; Rubin MA; Goodrich DW; Demichelis F; Sawyers CL
Science; 2017 Jan; 355(6320):84-88. PubMed ID: 28059768
[TBL] [Abstract][Full Text] [Related]
9. Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer.
Zou M; Toivanen R; Mitrofanova A; Floch N; Hayati S; Sun Y; Le Magnen C; Chester D; Mostaghel EA; Califano A; Rubin MA; Shen MM; Abate-Shen C
Cancer Discov; 2017 Jul; 7(7):736-749. PubMed ID: 28411207
[TBL] [Abstract][Full Text] [Related]
10. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer.
Brennen WN; Zhu Y; Coleman IM; Dalrymple SL; Antony L; Patel RA; Hanratty B; Chikarmane R; Meeker AK; Zheng SL; Hooper JE; Luo J; De Marzo AM; Corey E; Xu J; Yegnasubramanian S; Haffner MC; Nelson PS; Nelson WG; Isaacs WB; Isaacs JT
JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33724955
[TBL] [Abstract][Full Text] [Related]
11. Molecular events in neuroendocrine prostate cancer development.
Wang Y; Wang Y; Ci X; Choi SYC; Crea F; Lin D; Wang Y
Nat Rev Urol; 2021 Oct; 18(10):581-596. PubMed ID: 34290447
[TBL] [Abstract][Full Text] [Related]
12. Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers.
Rubin MA; Bristow RG; Thienger PD; Dive C; Imielinski M
Mol Cell; 2020 Nov; 80(4):562-577. PubMed ID: 33217316
[TBL] [Abstract][Full Text] [Related]
13. Molecular model for neuroendocrine prostate cancer progression.
Chen R; Dong X; Gleave M
BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer.
Gupta S; Vanderbilt C; Abida W; Fine SW; Tickoo SK; Al-Ahmadie HA; Chen YB; Sirintrapun SJ; Chadalavada K; Nanjangud GJ; Bialik A; Morris MJ; Scher HI; Ladanyi M; Reuter VE; Gopalan A
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):507-516. PubMed ID: 32094488
[TBL] [Abstract][Full Text] [Related]
15. A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations.
Kobayashi H; Kosaka T; Nakamura K; Shojo K; Hongo H; Mikami S; Nishihara H; Oya M
BMC Med Genomics; 2021 Oct; 14(1):245. PubMed ID: 34627261
[TBL] [Abstract][Full Text] [Related]
16. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
VanderLaan PA; Rangachari D; Mockus SM; Spotlow V; Reddi HV; Malcolm J; Huberman MS; Joseph LJ; Kobayashi SS; Costa DB
Lung Cancer; 2017 Apr; 106():17-21. PubMed ID: 28285689
[TBL] [Abstract][Full Text] [Related]
17. Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.
Hubbard GK; Mutton LN; Khalili M; McMullin RP; Hicks JL; Bianchi-Frias D; Horn LA; Kulac I; Moubarek MS; Nelson PS; Yegnasubramanian S; De Marzo AM; Bieberich CJ
Cancer Res; 2016 Jan; 76(2):283-92. PubMed ID: 26554830
[TBL] [Abstract][Full Text] [Related]
18. PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway.
Ni J; Zhou LL; Ding L; Zhao X; Cao H; Fan F; Li H; Lou R; Du Y; Dong S; Liu S; Wang Z; Ma R; Wu J; Feng J
Exp Cell Res; 2017 Dec; 361(2):246-256. PubMed ID: 29080795
[TBL] [Abstract][Full Text] [Related]
19. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
[TBL] [Abstract][Full Text] [Related]
20. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.
Dardenne E; Beltran H; Benelli M; Gayvert K; Berger A; Puca L; Cyrta J; Sboner A; Noorzad Z; MacDonald T; Cheung C; Yuen KS; Gao D; Chen Y; Eilers M; Mosquera JM; Robinson BD; Elemento O; Rubin MA; Demichelis F; Rickman DS
Cancer Cell; 2016 Oct; 30(4):563-577. PubMed ID: 27728805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
